Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

75.39 +18.91 (+33.47%)
Delayed Quote Updated: 11:16 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vaxcyte, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Monday's session: gap up and gap down stocks ↗
Via Chartmill
Discover the top movers in Monday's pre-market session. ↗
Via Chartmill
News headline image
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing ↗
Guggenhime surrendered shares to cover tax withholding on vesting RSUs, retaining about 164,000 shares valued at $10.12 million. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know ↗
Wassil exercised options at a steep discount and surrendered shares for tax withholding, maintaining a 0.1% ownership stake following the transactions. 
Via The Motley Fool
Topics Regulatory Compliance
Vaxcyte Inc (NASDAQ:PCVX) Reports Q4 2025 Results, Highlights Phase 3 Progress and Strong Cash Position ↗
Via Chartmill
News headline image
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm ↗
The stock has surged 95% over the past year, and the CEO retains about 447,000 direct shares plus indirect holdings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗
This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗
This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment. 
Via The Motley Fool
News headline image
The Small-Cap Renaissance: Why the Russell 2000 is Leading the Charge in 2026
As of March 9, 2026, a dramatic regime shift is unfolding on Wall Street. After years of playing second fiddle to the "Magnificent Seven" and AI-driven mega-caps, small-cap stocks have emerged as the... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Vaxcyte's Chief Technical Ops Officer Sells Shares ↗
Focused on next-generation vaccines for bacterial diseases, this biotech just reported a notable insider sale amid a challenging year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
These 3 Stocks Are Using Buybacks to Signal Market Confidence ↗
Via MarketBeat
News headline image
Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown ↗
Thermo Fisher sells four-part dollar bonds as U.S. investment-grade issuance tops $200 billion, with yields near historic lows and spreads tight. 
Via Benzinga
Topics Bonds
News headline image
Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data ↗
Merck's Capvaxive vaccine showed strong immune responses and a comparable safety profile to PPSV23 in high-risk children during the Phase 3 STRIDE-13 trial. 
Via Benzinga
News headline image
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Vaxcyte (PCVX) Q2 Loss Widens 11% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Monday's session: top gainers and losers ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet ↗
 
Via Benzinga
Topics Stocks
News headline image
Monday's pre-market session: top gainers and losers ↗
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.